Limaca Medical and HekaBio announce Japan partnership

This news appeared in PRNewswire, BioSpectrum Asia, Hospimedica. 

Limaca Medical and HekaBio K.K. announced that they have inked a strategic partnership agreement, whereby HekaBio is to distribute Limaca’s Precision-GI™ Endoscopic Biopsy Device in Japan.

Gastrointestinal-related cancer is a significant challenge in Japan. Although Japan’s adult population is just 40% of the US adult population, its pancreatic and liver cancer incidence almost matches the US in actual numbers.

Limaca’s vision is to ensure that endoscopic biopsies always achieve a definitive diagnosis to enable optimal and timely GI-cancer treatment. Limaca Medical, based in Israel, has as its mission to provide a far better endoscopic biopsy experience for the endoscopist and patient, with the goal to achieve a faster, more efficient biopsy yield with highly consistent results. Limaca recently announced the FDA’s decision to grant Breakthrough Device Designation to Precision-GI.

Limaca’s Precision-GI Endoscopic Biopsy Device

Limaca’s Precision-GI Endoscopic Biopsy Device

HekaBio is a Tokyo-based emerging major platform for healthcare innovation, with an initial focus on oncology and radiation therapy. HekaBio is dedicated to partnering with and investing in breakthrough technology originators to accelerate programs for commercialization in Japan and achieve significant benefits for patients and the healthcare system.

This partnership has far-reaching impact for Limaca, as HekaBio provides full operational capability in Japan for Limaca’s Precision-GI device and ensures compliance with Japan’s PMDA regulatory requirements. HekaBio will provide in-country logistics, physician training and case support.